CoChat

Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review

Open access
Schifano, Fabrizio, Chiappini, Stefania, Corkery, John, Guirguis, Amira · 2018 · Brain Sciences
Cited by 93

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Recently, a range of prescription and over-the-counter drugs have been reportedly used as Novel Psychoactive Substances (NPS), due to their potential for abuse resulting from their high dosage/idiosyncratic methods of self-administration. This paper provides a systematic review of the topic, focusing on a range of medications which have emerged as being used recreationally, either on their own or in combination with NPS. Among gabapentinoids, pregabalin may present with higher addictive liability levels than gabapentin, with pregabalin being mostly identified in the context of opioid, polydrug intake. For antidepressants, their dopaminergic, stimulant-like, bupropion activities may explain their recreational value and diversion from the therapeutic intended use. In some vulnerable clients, a high dosage of venlafaxine (‘baby ecstasy’) is ingested for recreational purposes, whilst the occurrence of a clinically-relevant withdrawal syndrome may be a significant issue for all venlafaxine-treated patients. Considering second generation antipsychotics, olanzapine appears to be ingested at very large dosages as an ‘ideal trip terminator’, whilst the immediate-release quetiapine formulation may possess proper abuse liability levels. Within the image- and performance- enhancing drugs (IPEDs) group, the beta-2 agonist clenbuterol (‘size zero pill’) is reported to be self-administered for aggressive slimming purposes. Finally, high/very high dosage ingestion of the antidiarrhoeal loperamide has shown recent increasing levels of popularity due to its central recreational, anti-withdrawal, opiatergic effects. The emerging abuse of prescription drugs within the context of a rapidly modifying drug scenario represents a challenge for psychiatry, public health and drug-control policies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/brainsci8040073

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 134

  1. Zawilska, 2015, Next generation of novel psychoactive substances on the horizon—A complex problem to face, Drug Alcohol Depend., 157, 1, 10.1016/j.drugalcdep.2015.09.030 · DOI · Paper page
  2. Hearne, 2017, New psychoactive substances (NPS) on crypto market fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors, Int. J. Drug Policy, 40, 102, 10.1016/j.drugpo.2016.11.007 · DOI
  3. Soussan, 2018, The diverse reasons for using Novel Psychoactive Substances—A qualitative study of the users’ own perspectives, Int. J. Drug Policy, 52, 71, 10.1016/j.drugpo.2017.11.003 · DOI
  4. Chiappini, 2018, Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency/EMA Adverse Drug Reactions’ database, J. Clin. Psychopharmacol., 38, 72, 10.1097/JCP.0000000000000814 · DOI · Paper page
  5. Milano, G., Chiappini, S., Mattioli, F., Martelli, A., and Schifano, F. (2018). β-2 agonists as misusing Drugs? Assessment of both Clenbuterol- and Salbutamol-related European Medicines Agency (EMA) Pharmacovigilance Database Reports. Basic Clin. Pharmacol. Toxicol., 2. · DOI
  6. Lasoff, 2017, Loperamide Trends in Abuse and Misuse Over 13 Years: 2002–2015, Pharmacotherapy, 37, 249, 10.1002/phar.1885 · DOI
  7. Schifano, 2014, Misuse and Abuse of Pregabalin and Gabapentin: Cause for Concern?, CNS Drugs, 28, 491, 10.1007/s40263-014-0164-4 · DOI · Paper page
  8. Evoy, 2017, Abuse and Misuse of Pregabalin and Gabapentin, Drugs, 77, 403, 10.1007/s40265-017-0700-x · DOI · Paper page
  9. Schjerning, 2016, Abuse Potential of Pregabalin: A Systematic Review, CNS Drugs, 30, 9, 10.1007/s40263-015-0303-6 · DOI · Paper page
  10. Schjerning, 2016, Use of Pregabalin—A Nationwide Pharmacoepidemiological Drug Utilization Study with Focus on Abuse Potential, Pharmacopsychiatry, 49, 155, 10.1055/s-0042-101868 · DOI
  11. Bonnet, 2017, How addictive are gabapentin and pregabalin? A systematic review, Eur. Neuropsychopharmacol., 27, 1185, 10.1016/j.euroneuro.2017.08.430 · DOI · Paper page
  12. Daly, C., Griffin, E., Ashcroft, D.M., Webb, R.T., Perry, I.J., and Arensman, E. (2017). Intentional Drug Overdose Involving Pregabalin and Gabapentin: Findings from the National Self-Harm Registry Ireland, 2007–2015. Clin. Drug Investig., 20. · DOI
  13. Reeves, 2014, Potentiation of the effect of buprenorphine/naloxone with gabapentin or quetiapine, Am. J. Psychiatry, 171, 691, 10.1176/appi.ajp.2014.13111526 · DOI · Paper page
  14. (2018, April 21). Greater use of gabapentinoids in intentional drug overdose. Available online: https://doi.org/10.1007/s40278-018-40617-3. · doi:10.1007/s40278-018-40617-3
  15. Anderson, 2017, Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis, JMIR Public Health Surveill., 3, e6, 10.2196/publichealth.6174 · DOI
  16. Evans, 2014, Abuse and misuse of antidepressants, Subst. Abuse Rehabil., 5, 107
  17. Welsh, 2002, Seizure-induced by insufflation of bupropion, N. Engl. J. Med., 347, 951, 10.1056/NEJM200209193471222 · DOI
  18. Reeves, 2013, Additional evidence of the abuse potential of bupropion, J. Clin. Psychopharmacol., 33, 584, 10.1097/JCP.0b013e318295fe2f · DOI
  19. Baribeau, 2013, Intravenous bupropion: A previously undocumented method of abuse of a commonly prescribed antidepressant agent, J. Addict. Med., 7, 216, 10.1097/ADM.0b013e3182824863 · DOI
  20. Prosser, 2012, The toxicology of bath salts: A review of synthetic cathinones, J. Med. Toxicol., 8, 33, 10.1007/s13181-011-0193-z · DOI · Paper page
  21. Stall, 2014, Bupropion abuse and overdose, CMAJ, 186, 1015, 10.1503/cmaj.131534 · DOI
  22. Stassinos, 2016, Bupropion “Abuse” Reported to US Poison Centers, J. Addict. Med., 10, 357, 10.1097/ADM.0000000000000249 · DOI
  23. Hill, 2007, Letter to the editor. A case report of seizure induced by bupropion nasal insufflation, J. Clin. Psychiatry, 9, 67
  24. Yoon, 2013, Intranasal bupropion abuse case report, Am. J. Addict., 22, 180, 10.1111/j.1521-0391.2013.00329.x · DOI
  25. Hilliard, 2013, Bupropion diversion and misuse in the correctional facility, J. Correct. Health Care, 19, 211, 10.1177/1078345813486448 · DOI
  26. Phillips, 2012, Wellbutrin: Misuse and abuse by incarcerated individuals, J. Addict. Nurs., 23, 65, 10.3109/10884602.2011.647838 · DOI
  27. Maj, 1999, Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the alpha 1-adrenergic, DA and serotonin systems, J. Neural Transm., 106, 197, 10.1007/s007020050151 · DOI
  28. Rakun, 2011, Venlafaxine withdrawal syndrome, Psychiatr. Danub., 23, 117
  29. Fava, 1997, Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine, Am. J. Psychiatry, 12, 1760, 10.1176/ajp.154.12.1760 · DOI · Paper page
  30. Stahl, 2005, SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants, CNS Spectr., 10, 732, 10.1017/S1092852900019726 · DOI · Paper page
  31. Llorca, 2007, Escitalopram in the treatment of major depressive disorder: Clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation, Int. J. Clin. Pract., 61, 702, 10.1111/j.1742-1241.2007.01335.x · DOI · Paper page
  32. Kotzalidis, 2008, Similar discontinuation symptoms for withdrawal from medium-dose paroxetine and venlafaxine, J. Psychopharmacol., 22, 581, 10.1177/0269881107081562 · DOI · Paper page
  33. Holland, 2017, Neonatal venlafaxine discontinuation syndrome: A mini-review, Eur. J. Paediatr. Neurol., 21, 264, 10.1016/j.ejpn.2016.11.003 · DOI
  34. Cutler, N. (2017). Severe Venlafaxine Withdrawal Successfully Treated With a Short Course of Duloxetine. Prim. Care Companion CNS Disord., 19. · DOI
  35. Groot, 2013, Consensus group Tapering. [Tapering strips for paroxetine and venlafaxine], Tijdschr. Psychiatr., 55, 789
  36. Francesconi, 2015, Venlafaxine as the ‘baby ecstasy’? Literature overview and analysis of web-based misusers’ experiences, Hum. Psychopharmacol., 30, 255, 10.1002/hup.2476 · DOI · Paper page
  37. Sattar, 2003, A case of venlafaxine abuse, N. Engl. J. Med., 348, 764, 10.1056/NEJM200302203480822 · DOI
  38. (2018, April 21). Venlafaxine overdose. Available online: https://doi.org/10.1007/s40278-018-40604-4. · doi:10.1007/s40278-018-40604-4
  39. Baker, 2014, Illicit and pharmaceutical drug consumption estimated via wastewater analysis. Part A: Chemical analysis and drug use estimates, Sci. Total Environ., 487, 629, 10.1016/j.scitotenv.2013.11.107 · DOI · Paper page
  40. Fountain, 2016, TOXINZ, the New Zealand Internet poisons information database: The first decade, Emerg. Med. Australas., 28, 335, 10.1111/1742-6723.12594 · DOI
  41. Bogart, 2011, Abuse of second-generation antipsychotics: What prescribers need to know, Curr. Psychiatry, 10, 77
  42. Sarker, 2016, Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter, Drug Saf., 39, 231, 10.1007/s40264-015-0379-4 · DOI · Paper page
  43. Majadas, 2008, Quetiapine in the treatment of sleep disturbances associated with addictive conditions: A retrospective study, Subst. Use Misuse, 43, 2169, 10.1080/10826080802290240 · DOI
  44. Srivastava, 2013, A Case Series of Quetiapine Addiction/Dependence, Ger. J. Psychiatr., 16, 152
  45. Kim, 2017, Quetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug-Seeking Behavior?, J. Res. Pharm. Pract., 6, 12, 10.4103/2279-042X.200987 · DOI · Paper page
  46. Waters, 2007, Intravenous Quetiapine-Cocaine Use (“Q-Ball”), Am. J. Psychiatry, 164, 173, 10.1176/ajp.2007.164.1.173a · DOI
  47. Pierre, 2004, Intranasal quetiapine abuse, Am. J. Psychiatry, 61, 1718, 10.1176/appi.ajp.161.9.1718 · DOI
  48. George, M., Haasz, M., Coronado, A., Salhanick, S., Korbel, L., and Kitzmiller, J.P. (2013). Acute dyskinesia, myoclonus, and akathisia in an adolescent male abusing quetiapine via nasal insufflation: A case study. BMC Pediatr., 13. · DOI
  49. Morin, 2007, Possible intranasal quetiapine misuse, Am. J. Health Syst. Pharm., 64, 723, 10.2146/ajhp060226 · DOI · Paper page
  50. Reeves, 2007, Additional evidence of the abuse potential of quetiapine, South. Med. J., 100, 834, 10.1097/SMJ.0b013e3180f62d53 · DOI · Paper page
  51. Paparrigopoulos, 2008, Quetiapine: Another drug with potential for misuse? A case report, J. Clin. Psychiatry, 69, 162, 10.4088/JCP.v69n0122a · DOI · Paper page
  52. Chen, 2009, Dependence on quetiapine in combination with zolpidem and clonazepam in bipolar depression, Psychiatry Clin. Neurosci., 63, 427, 10.1111/j.1440-1819.2009.01953.x · DOI · Paper page
  53. Sansone, 2010, Is Seroquel developing an illicit reputation for misuse/abuse?, Psychiatry, 7, 13
  54. Diot, 2015, Réseau de centres de d’Addictovigilance. Abuse Liability of Quetiapine (Xeroquel®): Analysis of the literature, Fundam. Clin. Pharmacol., 29, 27
  55. Haller, E., Bogunovic, O., and Miller, M. (2013, January 7). Atypical antipsychotics new drugs of abuse. Proceedings of the American Academy of Addiction Psychiatry (AAAP) 24th Annual Meeting & Symposium, Scottsdale, AZ, USA. Abstract 16.
  56. Mattson, 2015, Emergency Department Visits Involving Misuse and Abuse of the Antipsychotic Quetiapine: Results from the Drug Abuse Warning Network (DAWN), Subst. Abuse, 9, 39
  57. Klein, 2017, Intentional Recreational Abuse of Quetiapine Compared to Other Second-generation Antipsychotics, West. J. Emerg. Med., 18, 243, 10.5811/westjem.2016.10.32322 · DOI · Paper page
  58. Pinta, 2007, Letter to the editor. Quetiapine Addiction?, Am. J. Psychiatry, 164, 1, 10.1176/ajp.2007.164.1.174 · DOI
  59. Cha, 2013, Dependence potential of quetiapine: Behavioral pharmacology in rodents, Biomol. Ther., 21, 307, 10.4062/biomolther.2013.035 · DOI
  60. Kapur, 2000, Antipsychotic agents differ in how fast they come off the DA D2 receptors. Implications for atypical antipsychotic action, J. Psychiatry Neurosci., 25, 161
  61. Montebello, 2017, Misuse and Associated Harms of Quetiapine and Other Atypical Antipsychotics, Curr. Top. Behav. Neurosci., 34, 125, 10.1007/7854_2015_424 · DOI
  62. Navailles, 2011, Presynaptic control of serotonin on striatal DA function, Psychopharmacology, 213, 213, 10.1007/s00213-010-2029-y · DOI
  63. Kotagale, 2013, Evidences for the involvement of sigma receptors in antidepressant-like effect of quetiapine in mice, Eur. J. Pharmacol., 702, 180, 10.1016/j.ejphar.2013.01.045 · DOI
  64. Yasui, Y., and Su, T.P. (2016). Potential Molecular Mechanisms on the Role of the Sigma-1 Receptor in the Action of Cocaine and Methamphetamine. J. Drug Alcohol Res., 5. · DOI
  65. Grabowski, 2017, Quetiapine abuse and dependence: Is pharmacokinetics important?, Acta Clin. Belg., 13, 1
  66. Dahr, 2010, Olanzapine Dependence, Ger. J. Psychiatry, 13, 51
  67. James, 2016, Non-medical use of olanzapine by people on methadone treatment, BJPsych Bull., 40, 314, 10.1192/pb.bp.115.052886 · DOI · Paper page
  68. Skilbeck, 2007, The effects of antipsychotic drugs on GABAA receptor binding depend on period of drug treatment and binding site examined, Schizophr. Res., 90, 76, 10.1016/j.schres.2006.11.009 · DOI
  69. Egerton, 2008, Modulation of striatal DA release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat, Psychopharmacology, 200, 487, 10.1007/s00213-008-1226-4 · DOI
  70. Skov, 2015, Postmortem Quetiapine Reference Concentrations in Brain and Blood, J. Anal. Toxicol., 39, 557, 10.1093/jat/bkv072 · DOI
  71. Vance, 2009, Postmortem Tissue Concentrations of Olanzapine, J. Anal. Toxicol., 33, 15, 10.1093/jat/33.1.15 · DOI
  72. (2018, April 21). Aspirin/paracetamol/quetiapine overdose. Available online: https://doi.org/10.1007/s40278-018-40658-z. · doi:10.1007/s40278-018-40658-z
  73. (2018, April 21). Quetiapine/trazodone overdose. Available online: https://doi.org/10.1007/s40278-018-40528-4. · doi:10.1007/s40278-018-40528-4
  74. McVeigh, 2012, Human enhancement drugs and the pursuit of perfection, Adicciones, 24, 185, 10.20882/adicciones.88 · DOI
  75. Corazza, 2014, The diffusion of Performance and Image-Enhancing Drugs (IPEDs) on the Internet: The Abuse of the Cognitive Enhancer Piracetam, Subst. Use Misuse, 49, 1849, 10.3109/10826084.2014.912232 · DOI · Paper page
  76. Sagoe, 2015, Polypharmacy among anabolic-androgenic steroid users: A descriptive metasynthesis, Subst. Abuse Treat. Prev. Policy, 10, 12, 10.1186/s13011-015-0006-5 · DOI · Paper page
  77. Brennan, 2017, The injecting use of image and performance-enhancing drugs (IPED) in the general population: A systematic review, Health Soc. Care Community, 25, 1459, 10.1111/hsc.12326 · DOI
  78. Kean, 2015, An exploratory study of image and performance enhancement drug use in a male British South Asian community, Int. J. Drug Policy, 26, 860, 10.1016/j.drugpo.2015.03.002 · DOI
  79. Rowe, 2017, Risk and blood-borne virus testing among men who inject image and performance enhancing drugs, Sydney, Australia, Drug Alcohol Rev., 36, 658, 10.1111/dar.12467 · DOI
  80. Koenraadt, 2017, Exploring the relationship between online buyers and sellers of image and performance enhancing drugs (IPEDs): Quality issues, trust and self-regulation, Int. J. Drug Policy, 50, 48, 10.1016/j.drugpo.2017.09.004 · DOI
  81. Albertson, 2016, The Changing Drug Culture: Use and Misuse of Appearance- and Performance-Enhancing Drugs, FP Essent., 441, 30
  82. Cassidy, 1999, Insulin as a substance of misuse in a patient with insulin dependent diabetes mellitus, BMJ, 319, 1417, 10.1136/bmj.319.7222.1417 · DOI
  83. Grimmer, 2016, Rhabdomyolysis Secondary to Clenbuterol Use and Exercise, J. Emerg. Med., 50, e71, 10.1016/j.jemermed.2015.09.006 · DOI
  84. Mottram, D.R., and Chester, N. (2014). Drugs in Sports, Routledge. [6th ed.]. · doi:10.4324/9781315881935
  85. Quinley, 2016, Clenbuterol causing non-ST-segment elevation myocardial infarction in a teenage female desiring to lose weight: Case and brief literature review, Am. J. Emerg. Med., 34, 1739, 10.1016/j.ajem.2015.12.086 · doi:10.1016/j.ajem.2015.12.086
  86. Khalil, 2017, Clenbuterol Hydrochloride, Profiles Drug Subst. Excip. Relat. Methodol., 42, 91, 10.1016/bs.podrm.2017.02.002 · doi:10.1016/bs.podrm.2017.02.002
  87. Spiller, 2013, A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding, Subst. Abuse, 34, 306, 10.1080/08897077.2013.772083 · DOI
  88. Brett, 2014, Clenbuterol toxicity: A NSW poisons information centre experience, Med. J. Aust., 200, 219, 10.5694/mja13.10982 · DOI
  89. Tutelyan, 2013, Dietary supplements containing prohibited substances, Vopr. Pitan, 82, 6
  90. Solimini, 2017, Adulteration Practices of Psychoactive Illicit Drugs: An Updated Review, Curr. Pharm. Biotechnol., 18, 524, 10.2174/1389201018666170710184531 · doi:10.2174/1389201018666170710184531
  91. Barry, 2013, Case report and review of clenbuterol cardiac toxicity, J. Cardiol. Cases, 8, 131, 10.1016/j.jccase.2013.07.004 · doi:10.1016/j.jccase.2013.07.004
  92. Huckins, 2013, Myocardial ischemia associated with clenbuterol abuse: Report of two cases, J. Emerg. Med., 44, 444, 10.1016/j.jemermed.2012.02.057 · doi:10.1016/j.jemermed.2012.02.057
  93. Daubert, 2007, Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation, J. Med. Toxicol., 3, 56, 10.1007/BF03160909 · doi:10.1007/bf03160909
  94. Ferrua, 2009, Acute myocardial infarction due to coronary vasospasm and salbutamol abuse, Heart, 95, 673, 10.1136/hrt.2008.161638 · DOI
  95. Marte, 2010, Atrial fibrillation associated with chocolate intake abuse and chronic salbutamol inhalation abuse, Int. J. Cardiol., 145, e74, 10.1016/j.ijcard.2008.12.159 · DOI
  96. Boucher, 2011, Salbutamol misuse or abuse with fatal outcome: A case report, Hum. Exp. Toxicol., 30, 1869, 10.1177/0960327110388957 · DOI
  97. 1987, Effects of clenbuterol and prenalterol on performance during differential reinforcement of low response rate in the rat, J. Pharmacol. Exp. Ther., 241, 68, 10.1016/S0022-5347(25)00358-1 · DOI
  98. Edwards, 1979, Dependency upon salbutamol inhalers, Br. J. Psychiatry, 134, 624, 10.1192/bjp.134.6.624 · doi:10.1192/bjp.134.6.624
  99. Morgan, 1986, Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate, Br. J. Clin. Pharmacol., 22, 587, 10.1111/j.1365-2125.1986.tb02939.x · DOI · Paper page
  100. Pope, 2013, Adverse health consequences of performance-enhancing drugs: An Endocrine Society scientific statement, Endocr. Rev., 35, 341, 10.1210/er.2013-1058 · DOI · Paper page
  101. Lewis, 1993, A study of self- poisoning with oral salbutamol-laboratory and clinical features, Hum. Exp. Toxicol., 12, 397, 10.1177/096032719301200509 · doi:10.1177/096032719301200509
  102. Nicoli, 2013, Quantification of clenbuterol at trace level in human urine by ultra-high pressure liquid chromatography-tandem mass spectrometry, J. Chromatogr. A, 1292, 142, 10.1016/j.chroma.2012.12.008 · DOI
  103. Vaso, 2015, Use and abuse of medication during 2014 FIFA World Cup Brazil: A retrospective survey, BMJ Open, 5, E007608, 10.1136/bmjopen-2015-007608 · DOI
  104. Miller, 2017, Loperamide misuse and abuse, J. Am. Pharm. Assoc., 57, S45, 10.1016/j.japh.2016.12.079 · DOI
  105. Daniulaityte, 2013, “I just wanted to tell you that loperamide WILL WORK”: A web-based study of the extra-medical use of loperamide, Drug Alcohol Depend., 130, 241, 10.1016/j.drugalcdep.2012.11.003 · DOI
  106. Levine, 2007, “Pharming”: The abuse of prescription and over-the-counter drugs in teens, Curr. Opin. Pediatr., 19, 270, 10.1097/MOP.0b013e32814b09cf · DOI · Paper page
  107. Cooper, 2013, Over the counter medicine abuse—A review of the literature, J. Subst. Use, 18, 82, 10.3109/14659891.2011.615002 · DOI · Paper page
  108. Fox, 2005, The birth of the e-clinic. Continuity or transformation in the UK governance of pharmaceutical consumption?, Soc. Sci. Med., 61, 1474, 10.1016/j.socscimed.2005.03.011 · DOI
  109. Manchikanti, 2006, Prescription drug abuse: What is being done to address this new drug epidemic? Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources, Pain Physician, 9, 287
  110. Baker, 2007, Loperamide: A pharmacological review, Rev. Gastroenterol. Disord., 7, S11-8
  111. Jaffe, 1980, Abuse potential of loperamide, Clin. Pharmacol. Ther., 28, 812, 10.1038/clpt.1980.239 · DOI
  112. Wightman, 2016, Not your regular high: Cardiac dysrhythmias caused by loperamide, Clin. Toxicol., 54, 454, 10.3109/15563650.2016.1159310 · DOI
  113. Borron, 2017, Misuse and Abuse of Loperamide: A New Look at a Drug with “Low Abuse Potential”, J. Emerg. Med., 53, 73, 10.1016/j.jemermed.2017.03.018 · DOI
  114. Marraffa, 2014, Cardiac conduction disturbance after loperamide abuse, Clin. Toxicol., 52, 952, 10.3109/15563650.2014.969371 · DOI
  115. Stanciu, 2017, Loperamide, the “Poor Man’s Methadone”: Brief Review, J. Psychoact. Drugs, 49, 18, 10.1080/02791072.2016.1260188 · DOI
  116. Eggleston, 2016, Notes from the Field: Cardiac Dysrhythmias after Loperamide Abuse—New York, 2008–2016, MMWR Morb. Mortal Wkly. Rep., 65, 1276, 10.15585/mmwr.mm6545a7 · DOI
  117. Eggleston, 2017, Loperamide Abuse Associated With Cardiac Dysrhythmia and Death, Ann. Emerg. Med., 69, 83, 10.1016/j.annemergmed.2016.03.047 · DOI
  118. Bhatti, 2017, Loperamide metabolite-induced cardiomyopathy and QTc prolongation, Clin. Toxicol., 55, 659, 10.1080/15563650.2017.1304555 · DOI
  119. Kozak, 2017, Torsades de pointes with high-dose loperamide, J. Electrocardiol., 50, 355, 10.1016/j.jelectrocard.2017.01.011 · DOI
  120. Wu, 2017, Clinical Review: Loperamide Toxicity, Ann. Emerg. Med., 70, 245, 10.1016/j.annemergmed.2017.04.008 · DOI
  121. Feaster, 2016, Loperamide-Related Deaths in North Carolina, J. Anal. Toxicol., 40, 677, 10.1093/jat/bkw069 · DOI
  122. Swank, 2017, Adverse event detection using the FDA post-marketing drug safety surveillance system: Cardiotoxicity associated with loperamide abuse and misuse, J. Am. Pharm. Assoc., 57, S63, 10.1016/j.japh.2016.11.011 · DOI
  123. Church, 1994, Loperamide blocks high-voltage-activated calcium channels and N-methyl-D-aspartate-evoked responses in rat and mouse cultured hippocampal pyramidal neurons, Mol. Pharmacol., 45, 747, 10.1016/S0026-895X(25)10162-4 · DOI
  124. Yaksh, 1999, Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist- loperamide, Anesthesiology, 90, 225, 10.1097/00000542-199901000-00029 · DOI
  125. Kang, 2016, Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: Revelations from the opioid abuse epidemic, Naunyn Schmiedebergs Arch. Pharmacol., 389, 1133, 10.1007/s00210-016-1286-7 · DOI
  126. Zhou, 2004, Herbal modulation of P-glycoprotein, Drug Metab. Rev., 36, 57, 10.1081/DMR-120028427 · DOI · Paper page
  127. Corazza, 2013, Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: The outcomes of the ReDNet project, Hum. Psychopharmacol., 28, 317, 10.1002/hup.2299 · DOI · Paper page
  128. Larsen, 2018, Ventricular Tachycardia Triggered by Loperamide and Famotidine Abuse, Drug Saf. Case Rep., 5, 11, 10.1007/s40800-018-0077-0 · doi:10.1007/s40800-018-0077-0
  129. Sehring, 2017, Letter to the editor. Loperamide abuse and cardiotoxicity, J. Community Hosp. Intern. Med. Perspect., 7, 275, 10.1080/20009666.2017.1361294 · doi:10.1080/20009666.2017.1361294
  130. Orsolini, 2015, Mind navigators of chemicals’ experimenters? A web-based description of e-psychonauts, Cyberpsychol. Behav. Soc. Netw., 18, 296, 10.1089/cyber.2014.0486 · DOI · Paper page
  131. Johanson, 2009, Risk management post-marketing surveillance for the abuse of medications acting on the central nervous system: Expert panel report, Drug Alcohol Depend., 105, S65, 10.1016/j.drugalcdep.2009.08.006 · DOI
  132. Mackey, 2016, Digital danger: A review of the global public health, patient safety and cybersecurity threats posed by illicit online pharmacies, Br. Med. Bull., 118, 110, 10.1093/bmb/ldw016 · doi:10.1093/bmb/ldw016
  133. McColl, 2006, Research design strategies to evaluate the impact of formulations on abuse liability, Drug Alcohol Depend., 83, S52, 10.1016/j.drugalcdep.2006.01.015 · DOI
  134. Schifano, 2016, The consequences of drug misuse on post-marketing surveillance, Exp. Rev. Clin. Pharmacol., 9, 867, 10.1080/17512433.2016.1178571 · DOI · Paper page

Cited by

See all 93

Metadata

Authors
Schifano, F., Chiappini, S., Corkery, J., & Guirguis, A.
Venue
Brain Sciences
Publisher
MDPI AG
Published
2018-04-22
Volume
8
Issue
4
Pages
73
ISSN
2076-3425 (ISSN-L)
OpenAlex
W2802428576
Cited by
93
References
31
FWCI
2.89
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. https://app.cochat.ai/papers/10.3390/brainsci8040073
The paper
Schifano, F., Chiappini, S., Corkery, J., & Guirguis, A. (2018). Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. Brain Sciences. https://doi.org/10.3390/brainsci8040073

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.